基因阴性临床MEN1患者的临床病程与个体化管理启示
该回顾性队列比较39例基因阴性临床MEN1患者与63例基因阳性MEN1先证者,发现基因阴性者首发与第二原发表现年龄更大,疾病特异性生存更好,甲状旁腺单腺病变比例更高、十二指肠胰腺神经内分泌肿瘤多灶比例更低,提示需单独分类与定制监测。
要点
- 基因阴性临床MEN1患者首次及第二原发表现年龄均显著大于基因阳性先证者。
- 基因阴性者疾病特异性生存显著优于基因阳性先证者。
- 基因阴性者甲状旁腺切除术中47%为单腺病变,基因阳性者为0%。
核心结论
- 基因阴性临床MEN1患者的临床病程与基因阳性MEN1先证者不同,可能支持单独分类与定制监测方案。
研究设计与样本
- 回顾性队列研究,纳入39例基因阴性临床MEN1患者(男性33%)与63例基因阳性MEN1先证者(男性59%)。
- 主要结局为表现的年龄相关外显率,次要结局为疾病特异性生存与内分泌肿瘤临床病程。
主要发现
- 基因阴性患者末次随访年龄65岁,基因阳性先证者50岁(P < .001)。
- 基因阴性患者首次及第二次原发表现年龄显著更大,仅1例出现第三原发表现。
- 合并原发性甲状旁腺功能亢进与垂体腺瘤的基因阴性患者无一例发生十二指肠胰腺神经内分泌肿瘤。
- 基因阴性患者疾病特异性生存显著更好。
- 基因阴性患者甲状旁腺切除术中47%为单腺病变(基因阳性0%),十二指肠胰腺神经内分泌肿瘤多灶比例为17%(基因阳性68%)。
临床怎么用
- 对基因阴性临床MEN1患者可考虑与基因阳性者区分监测策略。
- 基因阴性患者接受甲状旁腺手术时,近半数无多腺病变证据,可评估针对性单腺手术的可行性。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether genotype-negative clinical multiple endocrine neoplasia type 1 patients derive equal benefit from prospective surveillance as genotype-positive patients. METHODS: In this retrospective cohort study, we compared genotype-negative patients with clinical multiple endocrine neoplasia type 1 with genotype-positive index cases. Primary outcome was age-related penetrance of manifestations; secondary outcomes were disease-specific survival and clinical course of endocrine tumors. RESULTS: We included 39 genotype-negative patients with clinical multiple endocrine neoplasia type 1 (Male: 33%) and 63 genotype-positive multiple endocrine neoplasia type 1 index cases (Male: 59%). Genotype-negative patients with clinical multiple endocrine neoplasia type 1 were 65 years old at last follow-up; genotype-positive multiple endocrine neoplasia type 1 index cases were 50 (P < .001). Genotype-negative patients with clinical multiple endocrine neoplasia type 1 were significantly older at their first and second primary manifestation. Only 1 developed a third primary manifestation. No genotype-negative patients with clinical multiple endocrine neoplasia type 1 with primary hyperparathyroidism and a pituitary adenoma developed a duodenopancreatic neuroendocrine tumor. Disease-specific survival was significantly better in genotype-negative patients with clinical multiple endocrine neoplasia type 1. In genotype-negative patients with clinical multiple endocrine neoplasia type 1, primary hyperparathyroidism was single-gland disease in 47% of parathyroidectomies versus 0% in genotype-positive multiple endocrine neoplasia type 1 index cases. In genotype-negative patients with clinical multiple endocrine neoplasia type 1, 17% of duodenopancreatic neuroendocrine tumors were multifocal versus 68% in genotype-positive multiple endocrine neoplasia type 1 index cases. Genotype-negative patients with clinical multiple endocrine neoplasia type 1 had more pituitary macroadenomas, fewer prolactinomas, and more somatotroph adenomas. CONCLUSION: Genotype-negative patients with clinical multiple endocrine neoplasia type 1 have a different clinical course than genotype-positive multiple endocrine neoplasia type 1 index cases. This may support a separate classification and a tailored surveillance regimen. Of the genotype-negative patients with clinical multiple endocrine neoplasia type 1 who had parathyroidectomy, almost half had no evidence of multigland disease and may be potential candidates for a more targeted single-gland approach.
引用
- Pieterman CRC, Hyde SM, Wu SY, et al. Understanding the clinical course of genotype-negative MEN1 patients can inform management strategies. Surgery. 2020. PMID: 32703679. doi:10.1016/j.surg.2020.04.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。